TRCT
MITO

Tower Research Capital (TRC)’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Tower Research Capital (TRC)’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67
Closed – – 6910
2021
Q3 		$0 Buy
+67
New +$91 ﹤0.01% 6448

Other funds holding MITO

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s MITO Position: Q4 2021 in Review

Tower Research Capital (TRC) sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q4 2021, closing a stake of 67 shares.

Tower Research Capital (TRC) first reported a position in MITO in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 15 funds tracked by Wall St. Rank hold MITO as of Q4 2021.

  • Tower Research Capital (TRC) reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q4 2021 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 67 Stealth BioTherapeutics Corp. ADS shares in Q4 2021.
  • Tower Research Capital (TRC) first reported a position in Stealth BioTherapeutics Corp. ADS in Q3 2021 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Stealth BioTherapeutics Corp. ADS position peaked at $0 in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q4 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2021, filed 14 Feb 2022.